BioSpace News Archive

Business

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

November 2, 2023
·
13 min read
Business

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023.

November 2, 2023
·
10 min read
Business

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2023, and provided a business update.

November 2, 2023
·
7 min read
Genetown

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

Akebia Therapeutics®, Inc. announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it originally entered into in November 2019.

November 2, 2023
·
4 min read
Business

IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow

IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.

November 2, 2023
·
2 min read
Genetown

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

GENFIT announced that it will present an update on its scientific and corporate progress at The Liver Meeting® 2023 organized by the American Association for the Study of Liver Diseases, which will take place in Boston, MA from November 10-14, 2023.

November 2, 2023
·
7 min read
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform.

November 2, 2023
·
3 min read
Biotech Bay

Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG

Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.

November 2, 2023
·
3 min read
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of nine studies (one oral and eight posters) at the annual American Society of Nephrology Kidney Week 2023 Convergence taking place in Philadelphia, PA, November 2-5.

November 2, 2023
·
13 min read
BioCapital

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

Ascentage Pharma announced that results from multiple clinical studies of the company’s novel drug candidate, olverembatinib, have been selected for presentations, including two Oral Reports, at the 65th American Society of Hematology Annual Meeting.

November 2, 2023
·
23 min read